Drug Profile
Research programme: ATR protein inhibitors - Merck Serono/Spanish National Cancer Research Centre
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Spanish National Cancer Research Centre
- Developer Merck Serono; Spanish National Cancer Research Centre
- Class
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Cancer in Spain
- 28 Jan 2018 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 18 Dec 2013 Preclinical trials in Cancer in Spain (unspecified route)